News
ORPOF
11.60
NaN%
--
OSE Immunotherapeutics to Present at Chardan Healthcare Conference in New York
TipRanks · 3d ago
OSE Immunotherapeutics Updates Share Capital and Voting Rights Structure
TipRanks · 10/07 16:39
OSE Immunotherapeutics Extends Cash Runway as Tedopi and Lusvertikimab Advance in Late-Stage Trials
TipRanks · 09/28 06:03
OSE Immunotherapeutics’ Tedopi Lung Cancer Trial Selected for Oral Presentation at ESMO 2026
TipRanks · 09/23 06:26
OSE Immunotherapeutics’ Partner Veloxis Starts Phase 2 Trial of Transplant Drug Pegrizeprument
TipRanks · 09/09 16:39
OSE Immunotherapeutics Updates Share Capital and Voting Rights After New Share Issuance
TipRanks · 09/07 16:46
OSE Immunotherapeutics Showcases Lead IBD Drug Lusvertikimab in Upcoming KOL Webcast
TipRanks · 08/28 06:15
OSE Immunotherapeutics Updates Share Capital and Voting Rights After New Equity Issuance
TipRanks · 08/26 16:37
Ose Immunotherapeutics resumed with a Buy at Kepler Cheuvreux
TipRanks · 03/26 09:05
More
Webull provides a variety of real-time ORPOF stock news. You can receive the latest news about Ose Immunotherapeutics Sa through multiple platforms. This information may help you make smarter investment decisions.
About ORPOF
OSE Immunotherapeutics SA, formerly Orphan Synergy Europe Pharma SA, is a France-based company, engaged in clinical stage biotechnological sector. It develops immunotherapies, directly or through partnerships, for the activation and regulation of the immune system in immuno-oncology and in autoimmune diseases. The Company's research and development in immunology is based on 3 platforms, such as T cell-based vaccines, Immuno-Oncology (myeloid targets) and Auto-Immunity & Inflammation. It provides technological and scientific platforms: neoepitopes, agonist or antagonist monoclonal antibodies, ideally positioned to fight cancer and autoimmune diseases.